New Study Shows Promising Results for ACOU085 in Preventing Cisplatin-Induced Hearing Loss

Exciting Advances in Ototoxicity Treatment: ACOU085 Shows Promise

In a significant breakthrough in the realm of inner ear treatment, Acousia Therapeutics GmbH, a clinical-stage biotechnology firm, announced encouraging top-line efficacy results for their novel therapeutic candidate, ACOU085 (known as Bimokalner). This innovative drug aims to address acute and chronic hearing loss, particularly focusing on preventing ototoxicity induced by cisplatin chemotherapy.

Study Overview

The recent Phase 2a PROHEAR Study, which was both exploratory and placebo-controlled, evaluated the efficacy of ACOU085 administered via a transtympanic injection. This particular study involved testicular cancer patients who faced a heightened risk of experiencing sensorineural hearing loss as a side effect of cisplatin treatment. A dose of 6 mg was given to gauge the protective effects against hearing loss.

Among the young participants, a staggering 90% exhibited signs of ototoxicity in at least one ear after receiving three cycles of cisplatin (300 mg/m²). Most notably, the hearing loss predominantly affected the extended high-frequency ranges (10–16 kHz) and ranged from mild to moderate severity.

Results and Implications

Preliminary results highlighted that patients treated with ACOU085 showcased a significant prevention of increases in pure-tone audiometry (PTA) thresholds at the impacted frequencies compared to those on the placebo. This represents a crucial development not only for those specifically undergoing treatment for cancer but also for wider applications in treating various forms of hearing loss.

Professor Hubert Löwenheim, who chairs Otorhinolaryngology – Head and Neck Surgery at Tübingen University Medical Center and supervised the PROHEAR Study, emphasized the potential of Kv7.4 activation through ACOU085. He described this as a novel therapeutic approach that addresses a pressing medical need left unmet by current device-based solutions. The findings create an opportunity for advancing Kv7.4 modulation, potentially extending its benefits to a broader patient population.

Management Insights

Tim Boelke, M.D., the CEO and CMO of Acousia Therapeutics, expressed his enthusiasm regarding the results. He stated, "Today represents an exciting advancement for cancer patients at risk of cisplatin-induced hearing loss. Our novel drug candidate has the potential to prevent permanent inner ear damage that is typically seen after cisplatin-based chemotherapy."

With plans for further discussions and potential collaborations, the Acousia team is set to participate in the upcoming BIO International Convention in San Diego from June 22 to 25, 2026. This allows them to engage with strategic partners for the next phases of clinical development.

About ACOU085

ACOU085 stands out as a first-in-class otoprotective agent that is administered via a slow-release gel formulation, marking a significant advancement in treating cisplatin-induced hearing loss. This condition results from irreversible damage to the cochlea's outer hair cells, which are crucial for hearing. The targeted modulation of the Kv7.4 potassium channel in these outer hair cells has been well-documented in preclinical studies, showing promising results in preserving hearing function.

In conclusion, the recent findings from the PROHEAR Study not only demonstrate the potential efficacy of ACOU085 in preventing chemotherapy-induced ototoxicity but also pave the way for future innovations surrounding hearing preservation methodologies. As research continues, the hope is that ACOU085 will change the landscape for patients experiencing drug-induced hearing loss.